Cyclooxygenases: structural, cellular, and molecular biology.
By W. Smith, D. Dewitt, R. Garavito. Annual Review of Biochemistry, 2000
2,939 citations recorded by the source corpus.
Subfields: Genetics, Molecular Biology, Pharmacology
View Paper: https://www.semanticscholar.org/paper/752c9501216b9514bf24e7cf09e9657fdb550b94
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Molecular Biology
In Pharmacology
Citations in the corpus
- A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity (2001, background): “This effect was not seen in all NSAIDs and seems not to be mediated by inhibition of cyclooxygenase (COX) activity, the principal pharmacological target of NSAID”
- Why there are two cyclooxygenase isozymes. (2001, background): “PGHS-2 is generally present in cells only during early stages of cell differentiation or replication (25).”
- Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition (2004, background): “Outstanding reviews of COX structure and enzyme kinetics have recently been written (Garavito and DeWitt, 1999; Marnett, 2000; Smith et al., 2000) and thus only the essential aspects of these topics needed to understand the pharmacology of NSAIDs are discussed here.”
- Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. (2008, background): “In response to a wide variety of stimuli, free AA is released which is subsequently converted via COX, lipoxygenase (LOX) and cytochrome P450 enzyme catalysis to various lipid mediators known collectively as eicosanoids (27).”
- Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic (2004, background): “Such changes may be associated with the ability of COX-2 to out-compete COX-1 for arachidonic acid when this substrate is present in low concentrations (5).”
- Flavonoids: an overview (2016, neutral): “COX is an endogenous enzyme which catalyses the conversion of arachidonic acid into prostaglandins and thromboxanes((66)).”
- The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. (2009, background): “In the initial cyclooxygenase reaction, the COX enzymes catalyse the formation of the unstable intermediate PGG2 (prostaglandin G2) from arachidonic acid, which is then converted into PGH2 (prostaglandin H2) by the peroxidase activity of COX [11].”